Figure 1
The flowchart for the study.
Table 1
Characteristics of included studies and populations.
| Study | Country | Study Design | Journal | Participants (n) | Age (mean SD) | Male (%) | T2DM | Chemotherapy | Cancer type | Follow-up (Months) | NOS | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SGLT2i | Control | SGLT2i | Control | SGLT2i | Control | |||||||||
| Gongora 2022 | USA | Retrospective cohort study | JACC: Heart Failure | 32 | 96 | 60 (11) | 60 (10) | 50 | 57 | Yes | Anthracyclines | Lymphoma, Breast cancer, Leukemia, Genitourinary,Gastrointestinal and other cancers | 18 | 8 |
| Perelman 2024 | Israel | Retrospective cohort study | Cardio-oncology | 24 | 95 | 70 (6) | 71 (11) | 79 | 58 | Yes | Immune checkpoint inhibitors | NSCLC, Melanoma, Renal cell carcinoma, Hepatocellular carcinoma, Breast cancer, Cenical Squamous, Other cancers | 28 | 7 |
| Fath 2024 | USA | Retrospective cohort study | The American Journal of Cardiology | 706 | 706 | 62.5 (10.1) | 62.4 (12.7) | 48 | 47 | Yes | Anthracyclines | Hematological and lymphatic, Breast, Gastrointestinal and digestive organs, Respiratory and intrathoracic organs, Endocrine glands and other cancers | 24 | 9 |
| Avula 2023 | USA | Retrospective cohort study | JACC: Heart Failure | 640 | 640 | 67.6 (10.8) | 67.6 (11.6) | 58.4 | 58.4 | Yes | Anthracyclines, Antimetabolites. Aromatase inhibitor, monoclonal antibodies, Proteosome inhibitors, Small molecular TKIs | Breast, Lymphomas, Myelodysplastic syndromes, Genitourinary,Gastrointestinal, Gynecologic and other cancers | 24 | 9 |
| Qadir 2023 | Canada | Retrospective cohort study | JACC: Cardiooncology | 99 | 834 | NS | NS | 35.4 | 38.1 | Yes | Anthracyclines | Breast cancer, Lymphoma, other maligancy | 19.2 | 9 |
| Chiang 2022 | USA | Retrospective cohort study | Heart | 878 | 878 | NS | NS | 54 | 52 | Yes | Antimetabolites, Platinum, Plant alkaloids, Anthracyclines, Tyrosine kinase inhibitors, HER2 inhibitors, Immune checkpoint inhibitor | Gastrointestinal, Genitourinary, Thoracic, Head and Neck, Breas, Hematologic, Skin, Other cancers | 18.8 | 9 |
| Hwang 2023 | South Korea | Retrospective cohort study | Scientific Reports | 779 | 2337 | 56 (10) | 62 (11) | 29 | 37 | Yes | Anthracyclines, Alkylating agents, HER2 inhibitor, VEGF targeting agents | Lymphoma, Breast cancer, Genitourinary, and other cancers | 40.8 | 7 |
| Huang 2024 | China (Taiwan) | Retrospective cohort study | Diabetes & Metabolism | 16711 | 33422 | 61 (110 | 62 (11) | 48 | 48 | Yes | Not specified | Pancreatic cancer, Hepatocellular carcinoma, Esophageal, head and neck, lung and other cancers | 57.6 | 9 |
| Luo 2023 | USA | Retrospective cohort study | British Journal of Cancer | 531 | 24384 | 73.5 (5.45) | 77 (6.73) | 54.24 | 50.82 | Yes | Not specified | Non-small cell lung cancer | 21.2 | 9 |
| Hendryx 2022 | USA | Retrospective cohort study | Plos One | 137 | 137 | 72.5 (5.20) | 74.9 (6.52) | 68.61 | 68.27 | Yes | Not specified | Hepatocellular carcinoma | 20.4 | 9 |
Figure 2
Comparison of mortality between groups, A: Total analysis; B: Sensitivity analysis. C: Results limited to anthracycline-based chemotherapy.
Figure 3
A: Comparison of heart failure between groups; B: Sensitivity analysis.
Figure 4
Comparison of arrhythmia (A) and ACS (B) between groups, ACS: acute coronary syndrome.
Figure 5
Comparison of safety outcomes between groups, A: Comparison of sepsis between groups, B: Comparison of urinary tract infection between groups, C: Comparison of kidney injury between groups, D: Comparison of hypoglycemia between groups, E: Comparison of ketoacidosis between groups.